Published in Int J Urol on June 20, 2011
Image-guided robotic interventions for prostate cancer. Nat Rev Urol (2013) 0.89
Editorial Comment to Risk factors for pelvic lymphoceles post-radical prostatectomy. Int J Urol (2011) 0.80
Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urol Ann (2015) 0.77
A rare aetiology for increased drain output following a robotic-assisted prostatectomy. BMJ Case Rep (2014) 0.75
Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol (2010) 4.60
Urethral stricture: etiology, investigation and treatments. Dtsch Arztebl Int (2013) 3.57
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol (2008) 3.37
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol (2008) 2.43
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int (2010) 2.26
The "all-seeing needle": initial results of an optical puncture system confirming access in percutaneous nephrolithotomy. Eur Urol (2011) 2.13
Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol (2010) 2.11
Dual energy CT characterization of urinary calculi: initial in vitro and clinical experience. Invest Radiol (2008) 2.08
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology (2011) 2.04
Contemporary management of postprostatectomy incontinence. Eur Urol (2011) 2.01
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol (2007) 1.74
Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology (2010) 1.70
Techniques and long-term results of surgical procedures for BPH. Eur Urol (2006) 1.65
Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology (2009) 1.63
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Preliminary results on the off-label use of duloxetine for the treatment of stress incontinence after radical prostatectomy or cystectomy. Eur Urol (2006) 1.59
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56
18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54
The place of additional individual psychotherapy in the treatment of alcoholism: a randomized controlled study in nonresponders to anticraving medication-results of the PREDICT study. Alcohol Clin Exp Res (2013) 1.52
High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51
Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50
Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology (2010) 1.49
The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49
Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology (2012) 1.48
Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol (2007) 1.46
Postprostatectomy incontinence: all about diagnosis and management. Eur Urol (2008) 1.44
Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43
The complex structure of the smooth muscle layer of spermatic veins and its potential role in the development of varicocele testis. Eur Urol (2006) 1.43
Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol (2009) 1.40
Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. Eur Urol (2010) 1.39
Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med (2010) 1.35
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol (2012) 1.24
Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year. Eur Urol (2009) 1.22
Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int (2009) 1.21
Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res (2007) 1.20
Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol (2004) 1.16
Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol (2009) 1.15
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol (2010) 1.14
Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol (2009) 1.14
Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid--first clinical experiences. Urology (2008) 1.12
Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol (2007) 1.12
Monitoring the coupling of the lithotripter therapy head with skin during routine shock wave lithotripsy with a surveillance camera. J Urol (2011) 1.11
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009) 1.09
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib. Clin Genitourin Cancer (2009) 1.08
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol (2010) 1.06
Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J Urol (2012) 1.05
Prospective assessment of malnutrition in urologic patients. Urology (2009) 1.05
Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol (2006) 1.05
In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res (2006) 1.04
Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med (Berl) (2011) 1.02
Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma. Urol Oncol (2012) 1.02
Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol (2010) 1.02
Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol (2009) 1.01
Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate (2008) 1.01
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol (2011) 1.00
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol (2011) 1.00
Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology (2008) 0.98
Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation. Eur Urol (2007) 0.97
CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells (2013) 0.96
Induction of immune mediators in glioma and prostate cancer cells by non-lethal photodynamic therapy. PLoS One (2011) 0.96
Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model. J Urol (2005) 0.96
CEACAM1: a novel urinary marker for bladder cancer detection. Eur Urol (2009) 0.95
Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int (2009) 0.92
Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol (2009) 0.92
Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int (2010) 0.91
In vitro investigations of repulsion during laser lithotripsy using a pendulum set-up. Lasers Med Sci (2011) 0.90
Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther (2009) 0.90
Detection of inguinal lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT: a prospective single-center study. Urol Oncol (2009) 0.90
Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol (2010) 0.90
Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol (2003) 0.90